{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:02:12Z","timestamp":1793995332542,"version":"4.8.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ad.2024.12.015","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T08:56:20Z","timestamp":1735030580000},"page":"T254-T280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["[Translated article] Consensus Statement From the Spanish Academy of Dermatology and Venereology (AEDV) Psoriasis Working Group (SWG) and Pediatric Working Group (PWG) on the Management of Pediatric Psoriasis"],"prefix":"10.1016","volume":"116","author":[{"given":"A.","family":"Vicente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"P\u00e9rez-Ferriols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Batalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Garc\u00eda-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Eiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"de Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"De La Cueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2024.12.015_bib0650","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2009.09593.x","article-title":"Epidemiology and comorbidity of psoriasis in children","volume":"162","author":"Augustin","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0655","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/PRBM.S117583","article-title":"Bidirectional relationships between psychological health and dermatological conditions in children","volume":"11","author":"Mitchell","year":"2018","journal-title":"Psychol Res Behav Manag"},{"key":"10.1016\/j.ad.2024.12.015_bib0660","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2133.2006.07185.x","article-title":"A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases","volume":"155","author":"Beattie","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0665","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1590\/S0365-05962012000300002","article-title":"Assessment of the quality of life of pediatric patients with the major chronic childhood skin diseases","volume":"87","author":"Manzoni","year":"2012","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0670","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archderm.141.12.1537","article-title":"Prevalence and treatment of psoriasis in the United Kingdom: a population-based study","volume":"141","author":"Gelfand","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0675","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/pde.12205","article-title":"Childhood psoriasis \u2013 an analysis of German health insurance data","volume":"31","author":"Matusiewicz","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0680","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1525-1470.2000.01746.x","article-title":"A comparative study of pediatric onset psoriasis with adult onset psoriasis","volume":"17","author":"Raychaudhuri","year":"2000","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0685","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamadermatol.2017.0499","article-title":"Pediatric psoriasis comorbidity screening guidelines","volume":"153","author":"Osier","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0690","doi-asserted-by":"crossref","first-page":"adv00660","DOI":"10.2340\/actadv.v101.981","article-title":"Physician-reported clinical unmet needs burden and treatment patterns of paediatric psoriasis patients: a US and EU real-world evidence study","volume":"102","author":"Seyger","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2024.12.015_bib0695","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1080\/09546634.2022.2059051","article-title":"Managing pediatric psoriasis: update on treatments and challenges-a review","volume":"33","author":"Hebert","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2024.12.015_bib0700","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0705","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00431-017-2985-x","article-title":"Treatment of severe psoriasis in children: recommendations of an Italian expert group","volume":"176","author":"Fortina","year":"2017","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.ad.2024.12.015_bib0710","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s13555-022-00758-2","article-title":"Update on the management of pediatric psoriasis: an Italian consensus","volume":"12","author":"Peris","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2024.12.015_bib0715","first-page":"959","article-title":"S2k guidelines for the treatment of psoriasis in children and adolescents \u2013 short version. Part 2","volume":"17","author":"Eisert","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ad.2024.12.015_bib0720","first-page":"856","article-title":"S2k guidelines for the treatment of psoriasis in children and adolescents - short version. Part 1","volume":"17","author":"Eisert","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ad.2024.12.015_bib0725","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ad.2021.10.003","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2024.12.015_bib0730","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ad.2022.01.024","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2024.12.015_bib0735","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1525-1470.2001.018003188.x","article-title":"Childhood psoriasis: a clinical review of 1262 cases","volume":"18","author":"Morris","year":"2001","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0740","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2133.2010.10196.x","article-title":"Juvenile psoriasis in European and Asian children: similarities and differences","volume":"164","author":"Chiam","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0745","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1442-200X.2006.02270.x","article-title":"Psoriasis in childhood and adolescence: evaluation of demographic and clinical features","volume":"48","author":"Seyhan","year":"2006","journal-title":"Pediatr Int"},{"key":"10.1016\/j.ad.2024.12.015_bib0750","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40257-013-0026-8","article-title":"Diagnosis and treatment of pediatric psoriasis: current and future","volume":"14","author":"Shah","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0755","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/pde.12072","article-title":"Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States","volume":"30","author":"Mercy","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0760","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.clindermatol.2007.08.009","article-title":"Childhood psoriasis","volume":"25","author":"Benoit","year":"2007","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0765","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/bjd.16326","article-title":"Health-related quality of life in adolescents with psoriasis: an interview-based study","volume":"178","author":"Randa","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0770","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1525-1470.2011.01489.x","article-title":"The burden of childhood psoriasis","volume":"28","author":"De Jager","year":"2011","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0775","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.smrv.2015.09.003","article-title":"Psoriasis and sleep disorders: a systematic review","volume":"29","author":"Gupta","year":"2016","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.ad.2024.12.015_bib0780","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0785","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: which therapy for which patient: focus on special populations and chronic infections","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0790","unstructured":"Dermatology AAo. Measure 410. Psoriasis: clinical response to oral systemic or biologic medications 2016. Available from: https:\/\/qpp.cms.gov\/docs\/QPP_quality_measure_specifications\/Claims-Registry-Measures\/2017_Measure_410_Claims.pdf [accessed 1.4.24]."},{"key":"10.1016\/j.ad.2024.12.015_bib0795","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/bjd.12437","article-title":"Clinical experience and psychometric properties of the Children's Dermatology Life Quality Index (CDLQI), 1995\u20132012","volume":"169","author":"Salek","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0800","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2133.2003.05157.x","article-title":"The Children's Dermatology Life Quality Index: validation of the cartoon version","volume":"148","author":"Holme","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0805","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/bjd.15120","article-title":"Validation of the Simplified Psoriasis Index in Dutch children and adolescents with plaque psoriasis","volume":"176","author":"van Geel","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0810","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ad.2021.10.003","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2024.12.015_bib0815","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jan.13818","article-title":"The fear of needles: a systematic review and meta-analysis","volume":"75","author":"McLenon","year":"2019","journal-title":"J Adv Nurs"},{"key":"10.1016\/j.ad.2024.12.015_bib0820","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s13555-018-0257-y","article-title":"Treatment of genital psoriasis: a systematic review","volume":"8","author":"Beck","year":"2018","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2024.12.015_bib0825","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2009.06.048","article-title":"Efficacy and safety of treatments for childhood psoriasis: a systematic literature review","volume":"62","author":"de Jager","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0830","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/pde.13422","article-title":"Use of topical therapies for pediatric psoriasis: a systematic review","volume":"35","author":"Kravvas","year":"2018","journal-title":"Pediatr Dermatol"},{"issue":"Pt 1","key":"10.1016\/j.ad.2024.12.015_bib0835","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0190-9622(97)70281-0","article-title":"Topical calcipotriol in childhood psoriasis","volume":"36","author":"Oranje","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0840","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jamadermatol.2017.3029","article-title":"Safety of systemic agents for the treatment of pediatric psoriasis","volume":"153","author":"Bronckers","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0845","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/jamadermatol.2019.3717","article-title":"Association between quality of life and improvement in psoriasis severity and extent in pediatric patients","volume":"156","author":"Bruins","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0850","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1525-1470.2007.00341.x","article-title":"Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients","volume":"24","author":"Brune","year":"2007","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0855","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1365-2133.1996.tb01501.x","article-title":"Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris","volume":"135","author":"Darley","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0860","first-page":"75","article-title":"An association of pediatric psoriasis with metabolic syndrome in Thai children: 20 years retrospective study","volume":"11","author":"Mhusakunchai","year":"2021","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.ad.2024.12.015_bib0865","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2133.2012.10996.x","article-title":"The influence of treatments in daily clinical practice on the Children's Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry","volume":"167","author":"Oostveen","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0870","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/jdv.12789","article-title":"Treatment of paediatric scalp psoriasis with calcipotriene\/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children's quality of life in daily practice","volume":"29","author":"Oostveen","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.12.015_bib0875","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjd.12621","article-title":"The effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis: a prospective comparison of regular day care and day care with telemedicine","volume":"170","author":"Oostveen","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0880","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF01955893","article-title":"Topical application of 1,25-dihydroxyvitamin D3 (calcitriol) is an effective and reliable therapy to cure skin lesions in psoriatic children","volume":"152","author":"Saggese","year":"1993","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.ad.2024.12.015_bib0885","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjd.12895","article-title":"Calcipotriol\/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort","volume":"171","author":"van Geel","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0890","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1517\/14656566.9.11.2001","article-title":"Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses","volume":"9","author":"Frangos","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"Pt 2","key":"10.1016\/j.ad.2024.12.015_bib0895","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/0190-9622(91)70319-W","article-title":"Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis","volume":"25","author":"Herz","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0900","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1365-2133.1998.02077.x","article-title":"A practical guide to topical therapy in children","volume":"138","author":"Long","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0905","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.annder.2019.07.005","article-title":"Proactive treatment in childhood psoriasis","volume":"147","author":"Lavaud","year":"2020","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.12.015_bib0910","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/archderm.143.9.1223","article-title":"Focal acne during topical tacrolimus therapy for vitiligo","volume":"143","author":"Bakos","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0915","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000278241","article-title":"Dithranol therapy in childhood psoriasis: unjustifiably on the verge of falling into oblivion","volume":"220","author":"de Jager","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2024.12.015_bib0920","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40272-023-00592-9","article-title":"Topical management of pediatric psoriasis: a review of new developments and existing therapies","volume":"26","author":"Lie","year":"2024","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.ad.2024.12.015_bib0925","first-page":"1","article-title":"Topical therapy for the management of childhood psoriasis: Part I","volume":"13","author":"Cordoro","year":"2008","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.ad.2024.12.015_bib0930","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0935","first-page":"855","article-title":"A double-blind, randomized clinical trial of 20% alpha\/poly hydroxy acid cream to reduce scaling of lesions associated with moderate, chronic plaque psoriasis","volume":"12","author":"Akamine","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0940","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0025-6196(11)62116-2","article-title":"Topical therapies for localized psoriasis","volume":"76","author":"Witman","year":"2001","journal-title":"May Clin Proc"},{"key":"10.1016\/j.ad.2024.12.015_bib0945","first-page":"275","article-title":"Childhood psoriasis: often favorable outcome","volume":"18","year":"2009","journal-title":"Prescrire Int"},{"key":"10.1016\/j.ad.2024.12.015_bib0950","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1365-4362.1999.00500.x","article-title":"The role of salicylic acid in the treatment of psoriasis","volume":"38","author":"Lebwohl","year":"1999","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0955","doi-asserted-by":"crossref","first-page":"302528","DOI":"10.1155\/2014\/302528","article-title":"Oxidative damage to nucleic acids and benzo(a)pyrene-7,8-diol-9,10-epoxide-DNA adducts and chromosomal aberration in children with psoriasis repeatedly exposed to crude coal tar ointment and UV radiation","volume":"2014","author":"Borska","year":"2014","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.ad.2024.12.015_bib0960","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13075-017-1410-1","article-title":"Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"19","author":"Schiff","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ad.2024.12.015_bib0965","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/1346-8138.13713","article-title":"Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: a multicenter, cohort study","volume":"44","author":"Ergun","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0970","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1159\/000521262","article-title":"Systemic methotrexate treatment in 42 children with severe plaque psoriasis: a retrospective study in China","volume":"238","author":"Wang","year":"2022","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2024.12.015_bib0975","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2024.12.015_bib0980","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/pde.14781","article-title":"Treatment utilization and drug survival of systemic medications among commercially insured children with psoriasis","volume":"38","author":"Wan","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0985","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/pde.12351","article-title":"A systematic review of systemic medications for pustular psoriasis in pediatrics","volume":"31","author":"Posso-De Los Rios","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib0990","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/jdv.12749","article-title":"Systemic treatments in paediatric psoriasis: a systematic evidence-based update","volume":"29","author":"van Geel","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.12.015_bib0995","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/bjd.18029","article-title":"Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study","volume":"181","author":"Tha\u00e7i","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1000","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3109\/09546634.2014.996515","article-title":"Methotrexate in pediatric plaque-type psoriasis: long-term daily clinical practice results from the Child-CAPTURE registry","volume":"26","author":"van Geel","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2024.12.015_bib1005","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamadermatol.2019.4835","article-title":"A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents","volume":"156","author":"Bronckers","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1010","first-page":"e9812","article-title":"FDA approved biologics: can etanercept and ustekinumab be considered a first-line systemic therapy for pediatric\/adolescents in moderate to severe psoriasis? A systematic review","volume":"12","author":"Aslam","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.ad.2024.12.015_bib1015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/09546634.2017.1364692","article-title":"Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study","volume":"29","author":"Di Lernia","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2024.12.015_bib1020","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jdv.17002","article-title":"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial","volume":"35","author":"Bodemer","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.12.015_bib1025","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaad.2010.02.060","article-title":"Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial","volume":"64","author":"Langley","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2024.12.015_bib1035","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jaad.2010.04.004","article-title":"Long-term etanercept in pediatric patients with plaque psoriasis","volume":"63","author":"Paller","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1040","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2015.09.056","article-title":"Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis","volume":"74","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjd.19147","article-title":"Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)","volume":"183","author":"Paller","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1050","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/jdv.15579","article-title":"Biological treatments for paediatric psoriasis: a retrospective observational study on biological drug survival in daily practice in childhood psoriasis","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.12.015_bib1055","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12\u201317 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1060","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamadermatol.2022.0655","article-title":"Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial","volume":"158","author":"Paller","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5152\/eurjrheum.2022.21090","article-title":"Oral or parenteral methotrexate for the treatment of polyarticular juvenile idiopathic arthritis","volume":"9","author":"Bakry","year":"2022","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1070","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0049-0172(95)80039-5","article-title":"Rheumatologic complications of vitamin A and retinoids","volume":"24","author":"Nesher","year":"1995","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ad.2024.12.015_bib1075","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2310\/7750.2006.00065","article-title":"Lack of significant skeletal changes after long-term, low-dose retinoid therapy: case report and review of the literature","volume":"10","author":"Halverstam","year":"2006","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2024.12.015_bib1080","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/bdr2.1799","article-title":"Risk management of teratogenic medicines: a systematic review","volume":"112","author":"Shroukh","year":"2020","journal-title":"Birth Defects Res"},{"key":"10.1016\/j.ad.2024.12.015_bib1085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaad.2021.08.066","article-title":"A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results","volume":"86","author":"Magnolo","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1090","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/bjd.13235","article-title":"Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12\u201317 years of age","volume":"171","author":"Gooderham","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/ajd.13471","article-title":"Use of narrowband ultraviolet B (NBUVB) in paediatric psoriasis: a systematic literature review and meta-analysis","volume":"62","author":"Kim","year":"2021","journal-title":"Aust J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1100","first-page":"348","article-title":"Psoriasis en la infancia","volume":"12","author":"Vicente","year":"2014","journal-title":"An Pediatr Contin"},{"key":"10.1016\/j.ad.2024.12.015_bib1105","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/biomedicines9080958","article-title":"Refractory pediatric psoriasis and atopic dermatitis: the importance of therapeutical adherence and biological management","volume":"9","author":"Kelly","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ad.2024.12.015_bib1110","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1525-1470.2008.00729.x","article-title":"Enhanced response of childhood psoriasis to narrow-band UV-B phototherapy with preirradiation use of mineral oil","volume":"25","author":"Jain","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1115","first-page":"323","article-title":"Efficacy and safety of etanercept in children and adolescents aged > or =8 years with severe plaque psoriasis","volume":"20","author":"Landells","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1120","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaad.2009.10.046","article-title":"Intermittent etanercept therapy in pediatric patients with psoriasis","volume":"63","author":"Siegfried","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1125","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4103\/0378-6323.66580","article-title":"Childhood psoriasis","volume":"76","author":"Dogra","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.ad.2024.12.015_bib1130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/pde.12429","article-title":"Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12\u201317 years","volume":"32","author":"Eichenfield","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1135","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1525-1470.2008.00773.x","article-title":"Phototherapy in childhood","volume":"25","author":"Ersoy-Evans","year":"2008","journal-title":"Pediatr Dermatol"},{"issue":"Pt 1","key":"10.1016\/j.ad.2024.12.015_bib1140","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0190-9622(99)70076-9","article-title":"Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris","volume":"40","author":"Walters","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/09546634.2017.1395798","article-title":"Efficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review","volume":"29","author":"Chen","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2024.12.015_bib1150","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3109\/09546634.2015.1115813","article-title":"Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis","volume":"27","author":"Bulbul Baskan","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2024.12.015_bib1155","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/09546634.2015.1034072","article-title":"Systemic cyclosporine treatment in severe childhood psoriasis: a retrospective chart review","volume":"28","author":"Dogra","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2024.12.015_bib1160","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2133.2012.11204.x","article-title":"Psoriasis in children: should we be worried about comorbidities?","volume":"168","author":"Wootton","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s42358-020-00136-6","article-title":"The musculoskeletal impairment negatively impacts the quality of life of children and adolescents with psoriasis","volume":"60","author":"Meneghetti","year":"2020","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1170","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1007\/s12325-021-01795-7","article-title":"Real-world claims analyses of comorbidity burden, treatment pattern healthcare resource utilization, and costs in pediatric psoriasis","volume":"38","author":"Edson-Heredia","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.ad.2024.12.015_bib1175","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/jamadermatol.2013.1078","article-title":"Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study","volume":"149","author":"Paller","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1180","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.12.015_bib1185","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jaad.2017.08.034","article-title":"Cardiovascular comorbidities of pediatric psoriasis among hospitalized children in the United States","volume":"77","author":"Kwa","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1190","doi-asserted-by":"crossref","first-page":"536.e1","DOI":"10.1016\/j.anpedi.2022.04.015","article-title":"La medida de la presi\u00f3n arterial en ni\u00f1os y adolescentes: elemento clave en la evaluaci\u00f3n de la hipertensi\u00f3n arterial","volume":"96","author":"\u00c1lvarez","year":"2022","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.ad.2024.12.015_bib1195","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00592-017-1000-3","article-title":"Psoriasis in children with type 1 diabetes: a new comorbidity to be considered?","volume":"54","author":"Di Costanzo","year":"2017","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.ad.2024.12.015_bib1200","first-page":"127","article-title":"Diabetes tipo 2 en la infancia y adolescencia","volume":"7","author":"Ros","year":"2009","journal-title":"An Pediatr Contin"},{"key":"10.1016\/j.ad.2024.12.015_bib1205","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(07)60958-1","article-title":"The metabolic syndrome in children and adolescents","volume":"369","author":"Zimmet","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2024.12.015_bib1210","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/pde.12218","article-title":"Prevalence of the metabolic syndrome in children with psoriatic disease","volume":"30","author":"Goldminz","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1215","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pcad.2018.06.004","article-title":"Overview of epidemiology and contribution of obesity and body fat distribution to cardiovascular disease: an update","volume":"61","author":"Pich\u00e9","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.ad.2024.12.015_bib1220","doi-asserted-by":"crossref","first-page":"e1569","DOI":"10.1210\/clinem\/dgz195","article-title":"International waist circumference percentile cutoffs for central obesity in children and adolescents aged 6\u201318 years","volume":"105","author":"Xi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ad.2024.12.015_bib1225","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12471-011-0237-7","article-title":"Different anthropometric adiposity measures and their association with cardiovascular disease risk factors: a meta-analysis","volume":"20","author":"van Dijk","year":"2012","journal-title":"Neth Heart J"},{"key":"10.1016\/j.ad.2024.12.015_bib1230","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ad.2024.12.015_bib1235","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/BOR.0b013e328348b278","article-title":"Psoriatic juvenile idiopathic arthritis: a tale of two subgroups","volume":"23","author":"Stoll","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1240","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1396-0296.2004.04039.x","article-title":"Pediatric psoriasis and psoriatic arthritis","volume":"17","author":"Lewkowicz","year":"2004","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2024.12.015_bib1245","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/09546634.2018.1476653","article-title":"Pediatric patients with psoriasis and psychiatric disorders: premorbidity and comorbidity in a case-control study","volume":"30","author":"Kara","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2024.12.015_bib1250","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaad.2011.11.948","article-title":"Risks of developing psychiatric disorders in pediatric patients with psoriasis","volume":"67","author":"Kimball","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1255","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1365-2133.2010.09993.x","article-title":"A cross-sectional study using the Children's Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores","volume":"163","author":"de Jager","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1260","first-page":"1057","article-title":"Skin disease in children: effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients","volume":"8","author":"Kelly","year":"2021","journal-title":"Children (Basel)"},{"key":"10.1016\/j.ad.2024.12.015_bib1265","series-title":"Bright futures: guidelines for health supervision of infants, children, and adolescents","author":"Hagan","year":"2017"},{"key":"10.1016\/j.ad.2024.12.015_bib1270","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000381913","article-title":"Epidemiology and comorbidity in children with psoriasis and atopic eczema","volume":"231","author":"Augustin","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2024.12.015_bib1275","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jpeds.2010.02.024","article-title":"Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996\u20132006","volume":"157","author":"Abramson","year":"2010","journal-title":"J Pediatr"},{"key":"10.1016\/j.ad.2024.12.015_bib1280","doi-asserted-by":"crossref","first-page":"e0140908","DOI":"10.1371\/journal.pone.0140908","article-title":"The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis","volume":"10","author":"Anderson","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ad.2024.12.015_bib1285","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jaad.2019.08.019","article-title":"Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study","volume":"82","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.12.015_bib1290","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000503062","article-title":"Tofacitinib in pediatric psoriasis: an open-label trial to study its safety and efficacy in children","volume":"236","author":"AlMutairi","year":"2020","journal-title":"Dermatology"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024010044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024010044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T08:56:57Z","timestamp":1742288217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731024010044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":129,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0001731024010044"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2024.12.015","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Consensus Statement From the Spanish Academy of Dermatology and Venereology (AEDV) Psoriasis Working Group (SWG) and Pediatric Working Group (PWG) on the Management of Pediatric Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.06.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}